Challenges and opportunities in targeting the menin–MLL interaction

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Pui CH, Gaynon PS, Boyett JM et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet359(9321),1909–1915. (2002).
  MedlineGoogle Scholar
• 2  Liu H, Cheng EH, Hsieh JJ. MLL fusions: pathways to leukemia. Cancer Biol. Ther.8(13),1204–1211 (2009).
  Medline CASGoogle Scholar
• 3  Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer.33(4),331–345 (2002).
  MedlineGoogle Scholar
• 4  Popovic R, Zeleznik-Le NJ. MLL: how complex does it get? J. Cell. Biochem.95(2),234–242 (2005).
  Medline CASGoogle Scholar
• 5  Meyer C, Schneider B, Jakob S et al. The MLL recombinome of acute leukemias. Leukemia20(5),777–784 (2006).
  Medline CASGoogle Scholar
• 6  Dou Y, Hess JL. Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia. Int. J. Hematol.87(1),10–18 (2008).
  Medline CASGoogle Scholar
• 7  Zeisig BB, Milne T, Garcia-Cuellar MP et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol. Cell. Biol.24(2),617–628 (2004).
  Medline CASGoogle Scholar
• 8  Milne TA, Martin ME, Brock HW, Slany RK, Hess JL. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer. Res.65(24),11367–11374 (2005).
  Medline CASGoogle Scholar
• 9  Milne TA, Dou Y, Martin ME, Brock HW, Roeder RG, Hess JL. MLL associates specifically with a subset of transcriptionally active target genes. Proc. Natl Acad. Sci. USA102(41),14765–14770 (2005).
  Medline CASGoogle Scholar
• 10  Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev.21(21),2762–2774 (2007).
  Medline CASGoogle Scholar
• 11  Owens BM, Hawley RG. HOX and non-HOX homeobox genes in leukemic hematopoiesis. Stem Cells.20(5),364–379. (2002).
  Medline CASGoogle Scholar
• 12  Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene.26(47),6766–6776. (2007).
  Medline CASGoogle Scholar
• 13  Rice KL, Licht JD. HOX deregulation in acute myeloid leukemia. J. Clin. Invest.117(4),865–868. (2007).
  Medline CASGoogle Scholar
• 14  Armstrong SA, Staunton JE, Silverman LB et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet.30(1),41–47 (2002).
  Medline CASGoogle Scholar
• 15  Ayton PM, Cleary ML: Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev.17(18),2298–2307 (2003).
  Medline CASGoogle Scholar
• 16  Slany RK. When epigenetics kills: MLL fusion proteins in leukemia. Hematol. Oncol.23(1),1–9 (2005).
  Medline CASGoogle Scholar
• 17  Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell123(2),207–218 (2005).▪▪ Described the discovery and validation of menin as a critical co-factor of MLL fusion proteins in leukemia and validated that interaction of MLL fusions with menin is required for development of leukemia in vivo in animal models.
  Medline CASGoogle Scholar
• 18  Chen YX, Yan J, Keeshan K et al. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc. Natl Acad. Sci. USA103(4),1018–1023 (2006).
  Medline CASGoogle Scholar
• 19  Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science276(5311),404–407 (1997).
  Medline CASGoogle Scholar
• 20  Guru SC, Goldsmith PK, Burns AL et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc. Natl Acad. Sci. USA95(4),1630–1634. (1998).
  Medline CASGoogle Scholar
• 21  Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res.67(15),7275–7283 (2007).▪ Studies demonstrating that short N-terminal fragment of MLL may function as a dominant negative inhibitor of the activity of MLL fusion proteins.
  Medline CASGoogle Scholar
• 22  Grembecka J, Belcher AM, Hartley T, Cierpicki T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J. Biol. Chem.285(52),40690–40698 (2010).▪ First characterization of the menin–MLL interaction using biochemical and biophysical methods and finding that there are two menin binding motifs within the N-terminus of MLL.
  Medline CASGoogle Scholar
• 23  Hughes CM, Rozenblatt-Rosen O, Milne TA et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell.13(4),587–597. (2004).
  Medline CASGoogle Scholar
• 24  Grembecka J, He S, Shi A et al. Menin–MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol.8(3),277–284 (2012).▪▪ Development of a first class of small molecule inhibitors of menin–MLL interaction and characterization of their activities in MLL leukemia cells.
  Medline CASGoogle Scholar
• 25  Shi A, Murai MJ, He S et al. Structural insights into inhibition of the bivalent menin–MLL interaction by small molecules in leukemia. Blood120(23),4461–4469 (2012).▪ Study reporting a first high resolution crystal structure of human menin with bound small molecule inhibitor targeting the MLL binding site.
  Medline CASGoogle Scholar
• 26  Yokoyama A, Wang Z, Wysocka J et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol.24(13),5639–5649. (2004).
  Medline CASGoogle Scholar
• 27  Cosgrove MS, Patel A. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. FEBS J.277(8),1832–1842 (2010).
  Medline CASGoogle Scholar
• 28  Slany RK. The molecular biology of mixed lineage leukemia. Haematologica94(7),984–993 (2009).
  Medline CASGoogle Scholar
• 29  Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu. Rev. Biochem.81,65–95 (2012).
  Medline CASGoogle Scholar
• 30  Dou Y, Milne TA, Ruthenburg AJ et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat. Struct. Mol. Biol.13(8),713–719 (2006).
  Medline CASGoogle Scholar
• 31  Dou Y, Milne TA, Tackett AJ et al. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell121(6),873–885 (2005).
  Medline CASGoogle Scholar
• 32  Milne TA, Hughes CM, Lloyd R et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl Acad. Sci. USA102(3),749–754 (2005).
  Medline CASGoogle Scholar
• 33  Onodera A, Yamashita M, Endo Y et al. STAT6-mediated displacement of polycomb by trithorax complex establishes long-term maintenance of GATA3 expression in T helper type 2 cells. J. Exp. Med.207(11),2493–2506 (2010).
  Medline CASGoogle Scholar
• 34  Thiel AT, Blessington P, Zou T et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell17(2),148–159 (2010).
  Medline CASGoogle Scholar
• 35  Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell14(1),36–46 (2008).
  Medline CASGoogle Scholar
• 36  Van Nuland R, Smits AH, Pallaki P, Jansen PW, Vermeulen M, Timmers HT. Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes. Mol. Cell. Biol.33(10),2067–2077 (2013).
  MedlineGoogle Scholar
• 37  Huang J, Gurung B, Wan B et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature482(7386),542–546 (2012).▪ Reported the first crystal structure of human menin bound to MLL.
  Medline CASGoogle Scholar
• 38  Agarwal SK, Jothi R. Genome-wide characterization of menin-dependent H3K4me3 reveals a specific role for menin in the regulation of genes implicated in MEN1-like tumors. PLoS ONE7(5),e37952 (2012).
  Medline CASGoogle Scholar
• 39  Scacheri PC, Davis S, Odom DT et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet.2(4),e51 (2006).
  MedlineGoogle Scholar
• 40  Li BE, Gan T, Meyerson M, Rabbitts TH, Ernst P. Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood122(12),2039–2046 (2013).▪ Demonstrated that menin is not a requisite cofactor for MLL1 during normal hematopoiesis and drugs disrupting menin–MLL1 interaction should not impair hematopoiesis.
  Medline CASGoogle Scholar
• 41  Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat. Rev. Cancer.5(5),367–375. (2005).
  Medline CASGoogle Scholar
• 42  Trump D, Farren B, Wooding C et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM89(9),653–669 (1996).
  Medline CASGoogle Scholar
• 43  Pannett AA, Thakker RV. Multiple endocrine neoplasia type 1. Endocr. Relat. Cancer6(4),449–473 (1999).
  Medline CASGoogle Scholar
• 44  Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA68(4),820–823 (1971).
  MedlineGoogle Scholar
• 45  Crabtree JS, Scacheri PC, Ward JM et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc. Natl Acad. Sci. USA98(3),1118–1123 (2001).
  Medline CASGoogle Scholar
• 46  Bertolino P, Tong WM, Galendo D, Wang ZQ, Zhang CX. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol. Endocrinol.17(9),1880–1892 (2003).
  Medline CASGoogle Scholar
• 47  Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat.29(1),22–32 (2008).
  Medline CASGoogle Scholar
• 48  Yaguchi H, Ohkura N, Takahashi M, Nagamura Y, Kitabayashi I, Tsukada T. Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol. Cell. Biol.24(15),6569–6580 (2004).
  Medline CASGoogle Scholar
• 49  Shimazu S, Nagamura Y, Yaguchi H, Ohkura N, Tsukada T. Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms. Cancer Sci.102(11),2097–2102 (2011).
  Medline CASGoogle Scholar
• 50  Murai MJ, Chruszcz M, Reddy G, Grembecka J, Cierpicki T. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J. Biol. Chem.286(36),31742–31748 (2011).
  Medline CASGoogle Scholar
• 51  Agarwal SK, Guru SC, Heppner C et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell96(1),143–152 (1999).
  Medline CASGoogle Scholar
• 52  Heppner C, Bilimoria KY, Agarwal SK et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene20(36),4917–4925. (2001).
  Medline CASGoogle Scholar
• 53  Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc. Natl Acad. Sci. USA98(7),3837–3842 (2001).
  Medline CASGoogle Scholar
• 54  Kim H, Lee JE, Cho EJ, Liu JO, Youn HD. Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res.63(19),6135–6139 (2003).
  Medline CASGoogle Scholar
• 55  Dreijerink KM, Mulder KW, Winkler GS, Hoppener JW, Lips CJ, Timmers HT. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res.66(9),4929–4935 (2006).
  Medline CASGoogle Scholar
• 56  Imachi H, Murao K, Dobashi H et al. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Breast Cancer Res. Treat.122(2),395–407 (2010).
  Medline CASGoogle Scholar
• 57  Schnepp RW, Hou Z, Wang H et al. Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Res.64(18),6791–6796 (2004).
  Medline CASGoogle Scholar
• 58  Jin S, Mao H, Schnepp RW et al. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res.63(14),4204–4210 (2003).
  Medline CASGoogle Scholar
• 59  Sukhodolets KE, Hickman AB, Agarwal SK et al. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol. Cell. Biol.23(2),493–509 (2003).
  Medline CASGoogle Scholar
• 60  Balogh K, Patocs A, Hunyady L, Racz K. Menin dynamics and functional insight: take your partners. Mol. Cell. Endocrinol.326(1–2),80–84 (2010).
  Medline CASGoogle Scholar
• 61  Matkar S, Thiel A, Hua X. Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem. Sci.38(8),394–402 (2013).
  Medline CASGoogle Scholar
• 62  Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol. Cell. Endocrinol. doi:10.1016/j.mce.2013.08.002 (2013) (Epub ahead of print).
  MedlineGoogle Scholar
• 63  Yang Y, Hua X. In search of tumor suppressing functions of menin. Mol. Cell Endocrinol.265–266, 34–41 (2007).
  MedlineGoogle Scholar
• 64  Karges W, Maier S, Wissmann A, Dralle H, Dosch HM, Boehm BO. Primary structure, gene expression and chromosomal mapping of rodent homologs of the MEN1 tumor suppressor gene. Biochim. Biophys. Acta1446(3),286–294 (1999).
  Medline CASGoogle Scholar
• 65  Papaconstantinou M, Maslikowski BM, Pepper AN, Bedard PA. Menin: the protein behind the MEN1 syndrome. Adv. Exp. Med. Biol.668,27–36 (2009).
  Medline CASGoogle Scholar
• 66  Gray FL, Murai MJ, Grembecka J, Cierpicki T. Detection of disordered regions in globular proteins using (1)(3)C-detected NMR. Protein Sci.21(12),1954–1960 (2012).
  Medline CASGoogle Scholar
• 67  Macconaill LE, Hughes CM, Rozenblatt-Rosen O, Nannepaga S, Meyerson M. Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583. Mol. Cancer Res.4(10),793–801 (2006).
  Medline CASGoogle Scholar
• 68  Francis J, Lin W, Rozenblatt-Rosen O, Meyerson M. The menin tumor suppressor protein is phosphorylated in response to DNA damage. PLoS ONE6(1),e16119 (2011).
  Medline CASGoogle Scholar
• 69  Feng ZJ, Gurung B, Jin GH, Yang XL, Hua XX. SUMO modification of menin. Am. J. Cancer Res.3(1),96–106 (2013).
  Medline CASGoogle Scholar
• 70  Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res.34(Web Server issue),W116–W118 (2006).
  Medline CASGoogle Scholar
• 71  White AW, Westwell AD, Brahemi G. Protein–protein interactions as targets for small-molecule therapeutics in cancer. Expert Rev. Mol. Med.10,e8 (2008).
  MedlineGoogle Scholar
• 72  Zhou H, Liu L, Huang J et al. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein–protein interaction. J. Med. Chem.56(3),1113–1123 (2013).
  Medline CASGoogle Scholar
• 73  Manka J, Daniels RN, Dawson E et al. Inhibitors of the menin-mixed lineage leukemia (MLL) interaction. In: Probe Reports from the NIH Molecular Libraries Program. Bethesda, MD, USA (2013).
  Google Scholar
• 74  Olsen JA, Banner DW, Seiler P et al. Fluorine interactions at the thrombin active site: protein backbone fragments H-C(alpha)-C=O comprise a favorable C-F environment and interactions of C-F with electrophiles. Chembiochem5(5),666–675 (2004).
  Medline CASGoogle Scholar
• 75  Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression and segmental identity in Mll-mutant mice. Nature378(6556),505–508 (1995).
  Medline CASGoogle Scholar
• 76  Guenther MG, Jenner RG, Chevalier B et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc. Natl Acad. Sci. USA102(24),8603–8608 (2005).
  Medline CASGoogle Scholar
• 77  Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ. MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc. Natl Acad. Sci. USA95(18),10632–10636 (1998).
  Medline CASGoogle Scholar
• 78  Mishra BP, Ansari KI, Mandal SS. Dynamic association of MLL1, H3K4 trimethylation with chromatin and Hox gene expression during the cell cycle. FEBS J.276(6),1629–1640 (2009).
  Medline CASGoogle Scholar
• 79  Ansari KI, Hussain I, Das HK, Mandal SS. Overexpression of human histone methylase MLL1 upon exposure to a food contaminant mycotoxin, deoxynivalenol. FEBS J.276(12),3299–3307 (2009).
  Medline CASGoogle Scholar
• 80  Ansari KI, Kasiri S, Mandal SS. Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo. Oncogene32(28),3359–3370 (2013).
  Medline CASGoogle Scholar
• 81  Takeda S, Liu H, Sasagawa S et al. HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. J. Clin. Invest.123(7),3154–3165 (2013).
  Medline CASGoogle Scholar
• 82  Xu B, Li SH, Zheng R et al. Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription. Proc. Natl Acad. Sci. USA110(43),17480–17485 (2013).▪ Study validating that menin promotes development of hepatocellular carcinoma and that drugs inhibiting the menin–MLL interaction might demonstrate activity in hepatocellular carcinoma.
  Medline CASGoogle Scholar
• 83  Gallo M, Ho J, Coutinho FJ et al. A tumorigenic MLL-homeobox network in human glioblastoma stem cells. Cancer Res.73(1),417–427 (2013).
  Medline CASGoogle Scholar
• 84  Heddleston JM, Wu Q, Rivera M et al. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ.19(3),428–439 (2012).
  Medline CASGoogle Scholar
• 85  Milne TA, Kim J, Wang GG et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol. Cell.38(6),853–863 (2010).
  Medline CASGoogle Scholar
• 86  Huo H, Magro PG, Pietsch EC, Patel BB, Scotto KW. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer. Res.70(21),8726–8735 (2010).
  Medline CASGoogle Scholar
• 87  Glaser S, Schaft J, Lubitz S et al. Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development133(8),1423–1432 (2006).
  Medline CASGoogle Scholar
• 88  Lubitz S, Glaser S, Schaft J, Stewart AF, Anastassiadis K. Increased apoptosis and skewed differentiation in mouse embryonic stem cells lacking the histone methyltransferase Mll2. Mol. Biol. Cell.18(6),2356–2366 (2007).
  Medline CASGoogle Scholar
• 89  Bogershausen N, Bruford E, Wollnik B. Skirting the pitfalls: a clear-cut nomenclature for H3K4 methyltransferases. Clin. Genet.83(3),212–214 (2013).
  Medline CASGoogle Scholar
• 90  Huntsman DG, Chin SF, Muleris M et al. MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines. Oncogene18(56),7975–7984 (1999).
  Medline CASGoogle Scholar
• 91  Natarajan TG, Kallakury BV, Sheehan CE et al. Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon. Cancer Cell Int.10,13 (2010).
  MedlineGoogle Scholar
• 92  Ansari KI, Kasiri S, Mishra BP, Mandal SS. Mixed lineage leukaemia-4 regulates cell-cycle progression and cell viability and its depletion suppresses growth of xenografted tumour in vivo. Br. J. Cancer107(2),315–324 (2012).
  Medline CASGoogle Scholar
• 93  Imachi H, Yu X, Nishiuchi T, Miyai Y, Masugata H, Murao K. Raloxifene inhibits menin-dependent estrogen receptor activation in breast cancer cells. J. Endocrinol. Invest.34(11),813–815 (2011).
  Medline CASGoogle Scholar
• 94  Smith MC, Gestwicki JE. Features of protein–protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert. Rev. Mol. Med.14,e16 (2012).
  MedlineGoogle Scholar